NOVANTA INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NOVANTA INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $521.29M | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $384.76M | Feb 28, 2018 |
| FY2015 | Dec 31, 2015 | $90.22M | Mar 2, 2016 |
| FY2015 | Oct 2, 2015 | $92.27M | Mar 2, 2016 |
| FY2015 | Jul 3, 2015 | $96.49M | Mar 2, 2016 |
| FY2015 | Apr 3, 2015 | $94.61M | Mar 2, 2016 |
| FY2015 | Dec 31, 2014 | $94.01M | Mar 2, 2016 |
| FY2015 | Sep 26, 2014 | $94.66M | Mar 2, 2016 |
| FY2015 | Jun 27, 2014 | $96.91M | Mar 2, 2016 |
| FY2015 | Mar 28, 2014 | $79.13M | Mar 2, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $980.60M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $949.25M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $881.66M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $860.90M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $706.79M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $590.62M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $626.10M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $614.34M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $521.29M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $384.76M | Feb 27, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $373.60M | Mar 2, 2016 |
| FY2014 | Dec 31, 2014 | $94.01M | Mar 9, 2015 |
| FY2014 | Sep 26, 2014 | $94.66M | Mar 9, 2015 |
| FY2014 | Jun 27, 2014 | $96.91M | Mar 9, 2015 |
| FY2014 | Mar 28, 2014 | $79.13M | Mar 9, 2015 |
| FY2014 | Dec 31, 2013 | $82.21M | Mar 9, 2015 |
| FY2014 | Sep 27, 2013 | $79.86M | Mar 9, 2015 |
| FY2014 | Jun 28, 2013 | $79.77M | Mar 9, 2015 |
| FY2014 | Mar 29, 2013 | $75.07M | Mar 9, 2015 |
| FY2013 | Dec 31, 2012 | $66.41M | Mar 13, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $435.28M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $421.55M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $399.90M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $378.47M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $300.33M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $244.52M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $262.09M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $261.53M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $220.53M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $162.45M | Feb 27, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.83M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $64.09M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $72.88M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $74.05M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $50.33M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $44.52M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $40.77M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $49.11M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $60.05M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $22.00M | Feb 27, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.01M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $110.58M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $110.50M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $103.08M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $64.05M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $55.89M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $55.28M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $71.01M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $57.57M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $32.96M | Feb 27, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.48M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $95.52M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $91.68M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $85.77M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $72.52M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $61.00M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $55.97M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $51.02M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $41.67M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $32.00M | Feb 27, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $195.66M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $175.94M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $164.46M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $158.90M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $129.16M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $109.85M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $118.41M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $115.90M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $101.65M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $81.30M | Feb 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $64.06M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $158.51M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $120.08M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $90.78M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $94.63M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $140.24M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $63.25M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $89.65M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $63.38M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $47.79M | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.63M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $17.16M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $19.96M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $19.64M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $19.98M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $10.52M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $10.74M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $14.66M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $9.09M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $8.46M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.81B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $1.39B | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $1.23B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $1.24B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.23B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $865.18M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $869.74M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $719.58M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $726.70M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $425.64M | Feb 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $492.82M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $642.81M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $552.60M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $663.63M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $706.59M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $388.37M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $452.56M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $351.32M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $368.24M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $166.77M | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.31B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $745.70M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $673.46M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $577.59M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $521.29M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $476.81M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $417.17M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $368.26M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $311.55M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $258.87M | Feb 28, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $647.35M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $584.10M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $484.51M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $478.90M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $479.50M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $285.98M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $274.71M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $217.66M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $210.99M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $108.13M | Feb 28, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $321.38M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $267.55M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $203.46M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $130.58M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $56.53M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $6.20M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($38.32M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($79.09M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | ($127.74M) | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | ($167.55M) | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $380.87M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $113.99M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $105.05M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $100.11M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $117.39M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $125.05M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $78.94M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $82.04M | Feb 26, 2020 |
| FY2019 | Dec 31, 2017 | $100.06M | Feb 26, 2020 |
| FY2019 | Dec 31, 2016 | $68.11M | Feb 26, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $42.50M | Mar 13, 2014 |
| FY2012 | Dec 31, 2012 | $50.00M | Mar 18, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | 1 | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | 1 | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | 1 | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Feb 27, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | 1 | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | 1 | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | 1 | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Feb 27, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 35.67M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | 35.94M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | 35.81M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | 35.71M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 35.60M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 35.16M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 35.05M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 34.89M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 34.60M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 34.46M | Feb 28, 2018 |